The Federal Circuit case of Gilead Sciences v. Natco Pharma has rendered several valuable patents newly vulnerable to invalidity based on nonstatutory double patenting, in particular, patents that protect pharmaceutical products and have patent term extension. This session will discuss protective measures that patentees may take for existing patents as well as risk mitigating strategies for patent families in prosecution.

Ability Level: Advanced

Session ID: 21152